The DRD2 gene in psychiatric and neurological disorders and its phenotypes
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The TaqIA D2 dopamine receptor (DRD2) minor (A1) allele was first associated with severe alcoholism a decade ago. Since then, studies both confirming and not confirmnning this finding were reported. However, a meta-analysis of a large number of Caucasian alcoholics (both more severe and less severe) and controls (both assessed and unassessed for substance use disorders) revealed a significantly higher frequency (p < 10(-6)) and prevalence (p < 10(-8)) of the DRD2 A1 allele in the alcoholics. Further analysis showed that the more severe alcoholics had a 3-fold higher prevalence of the DRD2 A1 allele than the assessed controls (p < 10(-10)), whereas no difference was found between the less severe alcoholics and the unassessed controls. DRD2 exonic or promoter mutations have not yet been associated with alcoholism, although two intronic variants at the TaqIB and intron 6 sites, which are in linkage disequilibrium with the TaqIA site, were associated with this disorder. Variants of the DRD2 gene have also been associated with cocaine, nicotine and opioid dependence, obesity and gambling. It is hypothesised that the DRD2 is a reinforcement or reward gene. Although less intensively studied than substance use disorders, the DRD2 gene has been implicated in Tourette's syndrome (TS), post-traumatic stress disorder (PTSD) and certain symptoms associated with affective disorders and schizophrenia. Further, DRD2 variants have been implicated in Parkinson's disease (PD) and in iatrogenically-induced movement disorders, as well as in certain migraineurs. Phenotypic differences have been associated with DRD2 variants. These include reduced D2 dopamine receptor numbers and diminished glucose metabolism in the brain of subjects who carry the DRD2 A1 allele. In addition, phenotypic differences have been found in neurocognitive and personality characteristics, and in treatment outcome of DRD2 variants. The involvement of the DRD2 gene in certain neuropsychiatric disorders opens up the potential of a targeted pharmacogenomic approach to the prevention and treatment of these disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regier, D. A. (1990) · JAMA · doi:10.1001/jama.1990.03450190043026 · Cited by 3,962
Drugs of abuse: anatomy, pharmacology and function of reward pathways
Koob, G. F. (1992) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(92)90060-j · Cited by 2,070
Wise, R. A., & Rompre, P.-P. (1989) · Annual Review of Psychology · doi:10.1146/annurev.ps.40.020189.001203 · Cited by 1,968
Ebstein, R. P., Novick, O., Umansky, R., Priel, B., Osher, Y., Blaine, D., Bennett, E. R., Nemanov, L., Katz, M., & Belmaker, R. H. (1996) · Nature Genetics · doi:10.1038/ng0196-78 · Cited by 1,475
Allelic Association of Human Dopamine D2 Receptor Gene in Alcoholism
Blum, K. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03440150063027 · Cited by 1,055
Volkow, N. D., Fowler, J. S., Wang, G., Hitzemann, R., Logan, J., Schlyer, D. J., Dewey, S. L., & Wolf, A. P. (1993) · Synapse · doi:10.1002/syn.890140210 · Cited by 924
Bennett, S. T., Lucassen, A. M., Gough, S. C. L., Powell, E. E., Undlien, D. E., Pritchard, L. E., Merriman, M. E., Kawaguchi, Y., Dronsfield, M. J., Pociot, F., et al. (1995) · Nature Genetics · doi:10.1038/ng0395-284 · Cited by 746 · cited 1×
“, [7]) or by other linkage techniques.”
The Dopamine D2 Receptor Locus as a Modifying Gene in Neuropsychiatric Disorders
Comings, D. E. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470130073032 · Cited by 587 · cited 4×
“[25] 3 41 60 22.”
BackgroundResultInfluentialThompson, J., Thomas, N., Singleton, A., Piggot, M., Lloyd, S., Perry, E. K., Morris, C. M., Perry, R. H., Ferrier, I. N., & Court, J. A. (1997) · Pharmacogenetics · doi:10.1097/00008571-199712000-00006 · Cited by 553
Risch, N., & Teng, J. (1998) · Genome Research · doi:10.1101/gr.8.12.1273 · Cited by 366
Cited by
The molecular genetics of cognition: dopamine, COMT and BDNF
Savitz, J., Solms, M., & Ramesar, R. (2006) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2005.00163.x · Cited by 320
R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice
Tong, Y., Pisani, A., Martella, G., Karouani, M., Yamaguchi, H., Pothos, E. N., & Shen, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906334106 · Cited by 304
Ritchie, T., & Noble, E. P. (2003) · Neurochemical Research · doi:10.1023/a:1021648128758 · Cited by 292
Self-citationGene-Environment Interaction in Psychological Traits and Disorders
Dick, D. M. (2011) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032210-104518 · Cited by 290
Attention-deficit/hyperactivity disorder (ADHD) and binge eating.
Cortese, S., Bernardina, B. D., & Mouren, M.-C. (2008) · Nutrition Reviews · doi:10.1111/j.1753-4887.2007.tb00318.x · Cited by 147
Metadata
- Authors
- Noble, E. P.
- Venue
- Pharmacogenomics
- Publisher
- Informa UK Limited
- Published
- 2000-08
- Volume
- 1
- Issue
- 3
- Pages
- 309-333
- ISSN
- 1462-2416 (ISSN-L)
- 1744-8042
- OpenAlex
- W2132601293
- Cited by
- 146
- References
- 13
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The DRD2 gene in psychiatric and neurological disorders and its phenotypes. https://app.cochat.ai/papers/10.1517/14622416.1.3.309
- The paper
- Noble, E. P. (2000). The DRD2 gene in psychiatric and neurological disorders and its phenotypes. Pharmacogenomics. https://doi.org/10.1517/14622416.1.3.309
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.